FDA Approval For Novartis’s Sickle Cell Treatment Adakveo
Gains Nod Ahead Of Global Blood Therapeutics’ Contender
One of a new wave of treatments, Novartis has focused on proving its drug cuts vaso-occlusive crises (VOCs), or pain crises.
You may also be interested in...
Pfizer In Pole Position To Benefit From Novartis Sickle Cell Drug Setback
Pfizer joined Novartis as the market leader in sickle cell disease when it acquired Global Blood Therapeutics last year. The US giant's Oxbryta may now move ahead following a clinical and regulatory setback for the Swiss major's Adakveo.
Pfizer’s Buying Spree Continues With GBT, Gaining A Sickle Cell Disease Franchise
Pfizer has reached a deal to buy Global Blood Therapeutics for $5.4bn, gaining the sickle cell therapy Oxbryta and building on efforts to reach underserved patient groups.
GBT Bucks Gene Therapy Trend With Sanofi Sickle Cell Deal
Building on Oxbryta, which is already approved in the US for the rare blood disorder, Global Blood Therapeutics has licensed two sickle cell disease programs from Sanofi.